NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $511.82 -10.41 (-1.99%) Closing price 04:00 PM EasternExtended Trading$511.47 -0.35 (-0.07%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDGL alerts:Sign Up Key Stats Today's Range$508.86▼$528.9950-Day Range$431.53▼$546.8952-Week Range$265.00▼$615.00Volume258,876 shsAverage Volume347,183 shsMarket Capitalization$11.80 billionP/E RatioN/ADividend YieldN/APrice Target$687.00Consensus RatingModerate Buy Company Overview Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH. Resmetirom has been engineered to target liver tissue in order to reduce hepatic fat accumulation, improve lipid profiles and attenuate fibrosis. The company’s clinical programs include global trials across North America, Europe and Latin America, reflecting its commitment to registering resmetirom in major markets. In addition to its lead asset, Madrigal is advancing next-generation compounds for lipid disorders and other cardiovascular risk factors. The company engages in strategic collaborations to bolster its research capabilities and expand its therapeutic portfolio. Through a combination of in-house development and partnerships, Madrigal aims to bring multiple first-in-class or best-in-class therapies to patients. Founded in 2013 and headquartered in Conshohocken, Pennsylvania, Madrigal is led by President and Chief Executive Officer Paul A. Friedman, M.D. The company’s management team comprises experienced biopharmaceutical executives and clinical researchers dedicated to transforming the treatment landscape for metabolic and liver diseases.AI Generated. May Contain Errors. Read More Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreMDGL MarketRank™: Madrigal Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 445th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialMadrigal Pharmaceuticals has a consensus price target of $687.00, representing about 34.2% upside from its current price of $511.82.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($6.49) to $9.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -39.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -39.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 19.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.29% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 16.47, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 3.95%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.24 News SentimentMadrigal Pharmaceuticals has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,061,673.00 in company stock.Percentage Held by Insiders17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDGL Stock News HeadlinesDavid Soergel Sells 844 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMay 19 at 4:35 AM | insidertrades.comA Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales GrowthMay 11, 2026 | finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 19 at 1:00 AM | American Alternative (Ad)What is HC Wainwright's Forecast for MDGL FY2029 Earnings?May 11, 2026 | americanbankingnews.comMadrigal Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 9, 2026 | seekingalpha.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from BarclaysMay 9, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)May 9, 2026 | theglobeandmail.comH.C. Wainwright Remains a Buy on Madrigal Pharmaceuticals (MDGL)May 7, 2026 | theglobeandmail.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $582.34 on January 1st, 2026. Since then, MDGL stock has decreased by 12.1% and is now trading at $511.82. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($3.25) EPS for the quarter, beating analysts' consensus estimates of ($3.61) by $0.36. The business's revenue was up 126.8% on a year-over-year basis. Read the conference call transcript. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional investors include Janus Henderson Group PLC (8.75%), Paulson & CO. Inc. (6.04%), Bank of America Corp DE (0.82%) and Pictet Asset Management Holding SA (0.82%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Shannon T Kelley, David Soergel, Fred B Craves, Robert E Waltermire, Kenneth Bate and James M Daly. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MDGL's financial health is in the Green zone, according to TradeSmith. MDGL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees90Year Founded2011Price Target and Rating Average Price Target for Madrigal Pharmaceuticals$687.00 High Price Target$964.00 Low Price Target$529.00 Potential Upside/Downside+34.2%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($12.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$288.28 million Net Margins-27.32% Pretax Margin-27.32% Return on Equity-50.15% Return on Assets-25.44% Debt Debt-to-Equity Ratio0.63 Current Ratio3.50 Quick Ratio3.16 Sales & Book Value Annual Sales$958.40 million Price / Sales12.31 Cash FlowN/A Price / Cash FlowN/A Book Value$26.54 per share Price / Book19.28Miscellaneous Outstanding Shares23,060,000Free Float18,998,000Market Cap$11.80 billion OptionableOptionable Beta-1.04 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:MDGL) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
